LivaNova PLC (LIVN)

$50.04 $0.17 (0.34%) 4:37 PM 12/10/24
NASDAQ | $USD | Medical Devices

Stock Data

  • Market Cap

    $2.70B

  • Day's Range

    $49.55 - $50.46

  • Volume

    453,148

  • 52 Week Low / High

    $43.15 - $64.48

  • PE Ratio

    115.60x

  • PEG Ratio

    0.47

  • Dividend Frequency

    -

LIVN's Dividend
-
Amount
-
Dividend Yield
-
Payment Date
-
Annual Dividend Amount
Dividend Streak
Hypothetical 10k Investment Jan 1, 2020
Capital Growth
Dividend Return to Date
Dividend Payout year Est.
Expenses
Total Return
Total Return %
Analyists Ranking
5
Strong Buy
3
Buy
3
Hold
0
Sell
0
Strong Sell
$64.56
Target Price

Company News

  • LivaNova Appoints Susan Podlogar as a New Director — Oct 8th, 2024

    LONDON, October 08, 2024--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, announced its Board of Directors has appointed Susan Podlogar to the Board, effective today. Podlogar will serve on the Compensation and Human Capital Management Committee f...

  • LivaNova Appoints Susan Podlogar as a New Director — Oct 8th, 2024

    LONDON, October 08, 2024--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, announced its Board of Directors has appointed Susan Podlogar to the Board, effective today. Podlogar will serve on the Compensation and Human Capital Management Committee f...

  • LivaNova Appoints Susan Podlogar as a New Director — Oct 8th, 2024

    LONDON, October 08, 2024--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, announced its Board of Directors has appointed Susan Podlogar to the Board, effective today. Podlogar will serve on the Compensation and Human Capital Management Committee f...

  • LivaNova to Announce Third-Quarter 2024 Results — Sep 25th, 2024

    LONDON, September 25, 2024--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its third-quarter 2024 results on Wednesday, October 30, 2024 at 12 p.m. London time (8 a.m. Eastern Time). The Company will release...

  • LivaNova PLC (LIVN) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ... — Oct 9th, 2024

    Revenue: $319 million, an increase of 10% versus 2023. Cardiopulmonary Segment Revenue: $174 million, an increase of 14% versus Q2 2023. Heart-Lung Machine Revenue: Increased over 25% driven by Essenz. Oxygenator Revenue: Grew more than 15% driven by customer demand and price. Epilepsy Rev...

  • LivaNova Appoints Susan Podlogar as a New Director — Oct 8th, 2024

    LONDON, October 08, 2024--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, announced its Board of Directors has appointed Susan Podlogar to the Board, effective today. Podlogar will serve on the Compensation and Human Capital Management Committee f...

  • LivaNova PLC (LIVN) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ... — Oct 9th, 2024

    Revenue: $319 million, an increase of 10% versus 2023. Cardiopulmonary Segment Revenue: $174 million, an increase of 14% versus Q2 2023. Heart-Lung Machine Revenue: Increased over 25% driven by Essenz. Oxygenator Revenue: Grew more than 15% driven by customer demand and price. Epilepsy Rev...

  • LivaNova Appoints Susan Podlogar as a New Director — Oct 8th, 2024

    LONDON, October 08, 2024--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, announced its Board of Directors has appointed Susan Podlogar to the Board, effective today. Podlogar will serve on the Compensation and Human Capital Management Committee f...

  • LivaNova PLC (LIVN) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ... — Oct 9th, 2024

    Revenue: $319 million, an increase of 10% versus 2023. Cardiopulmonary Segment Revenue: $174 million, an increase of 14% versus Q2 2023. Heart-Lung Machine Revenue: Increased over 25% driven by Essenz. Oxygenator Revenue: Grew more than 15% driven by customer demand and price. Epilepsy Rev...

  • LivaNova to Announce Third-Quarter 2024 Results — Sep 25th, 2024

    LONDON, September 25, 2024--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its third-quarter 2024 results on Wednesday, October 30, 2024 at 12 p.m. London time (8 a.m. Eastern Time). The Company will release...

  • LivaNova PLC (LIVN) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ... — Oct 9th, 2024

    Revenue: $319 million, an increase of 10% versus 2023. Cardiopulmonary Segment Revenue: $174 million, an increase of 14% versus Q2 2023. Heart-Lung Machine Revenue: Increased over 25% driven by Essenz. Oxygenator Revenue: Grew more than 15% driven by customer demand and price. Epilepsy Rev...

  • LivaNova Appoints Susan Podlogar as a New Director — Oct 8th, 2024

    LONDON, October 08, 2024--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, announced its Board of Directors has appointed Susan Podlogar to the Board, effective today. Podlogar will serve on the Compensation and Human Capital Management Committee f...

  • LivaNova PLC (LIVN) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ... — Oct 9th, 2024

    Revenue: $319 million, an increase of 10% versus 2023. Cardiopulmonary Segment Revenue: $174 million, an increase of 14% versus Q2 2023. Heart-Lung Machine Revenue: Increased over 25% driven by Essenz. Oxygenator Revenue: Grew more than 15% driven by customer demand and price. Epilepsy Rev...

  • LivaNova PLC (LIVN) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ... — Oct 9th, 2024

    Revenue: $319 million, an increase of 10% versus 2023. Cardiopulmonary Segment Revenue: $174 million, an increase of 14% versus Q2 2023. Heart-Lung Machine Revenue: Increased over 25% driven by Essenz. Oxygenator Revenue: Grew more than 15% driven by customer demand and price. Epilepsy Rev...

  • LivaNova PLC (LIVN) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ... — Oct 9th, 2024

    Revenue: $319 million, an increase of 10% versus 2023. Cardiopulmonary Segment Revenue: $174 million, an increase of 14% versus Q2 2023. Heart-Lung Machine Revenue: Increased over 25% driven by Essenz. Oxygenator Revenue: Grew more than 15% driven by customer demand and price. Epilepsy Rev...

  • LivaNova PLC (LIVN) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ... — Oct 9th, 2024

    Revenue: $319 million, an increase of 10% versus 2023. Cardiopulmonary Segment Revenue: $174 million, an increase of 14% versus Q2 2023. Heart-Lung Machine Revenue: Increased over 25% driven by Essenz. Oxygenator Revenue: Grew more than 15% driven by customer demand and price. Epilepsy Rev...

  • LivaNova Appoints Susan Podlogar as a New Director — Oct 8th, 2024

    LONDON, October 08, 2024--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, announced its Board of Directors has appointed Susan Podlogar to the Board, effective today. Podlogar will serve on the Compensation and Human Capital Management Committee f...

  • LivaNova Appoints Susan Podlogar as a New Director — Oct 8th, 2024

    LONDON, October 08, 2024--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, announced its Board of Directors has appointed Susan Podlogar to the Board, effective today. Podlogar will serve on the Compensation and Human Capital Management Committee f...

Similar Stocks

Want to be notified on dividend changes?

Start manging your portfolio today.

Sign up for free